Product
obinutuzumab
Aliases
Gazyva
3 clinical trials
5 indications
Indication
Mature B-Cell MalignanciesIndication
Chronic Lymphocytic LeukemiaIndication
Small Lymphocytic LymphomaIndication
Aggressive LymphomaIndication
Follicular LymphomaClinical trial
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell MalignanciesStatus: Recruiting, Estimated PCD: 2027-08-30
Clinical trial
A Phase I/II Dose-Escalation and Expansion Study of the Selective PKC-β Inhibitor MS-553 in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaStatus: Recruiting, Estimated PCD: 2024-04-15
Clinical trial
Post-Marketing Surveillance of Gazyva in Treatment of Patients With Gazyva in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia PatientsStatus: Completed, Estimated PCD: 2022-11-10